Boan Biotech，a holding subsidiary of Luye Pharma Group, announced that its biopharmaceutical drug 博优诺®(Bevacizumab Injection) has received marketing authorization from China’s National Medic...
Luye Pharma Group today announced that Nivolumab injection (LY01015) developed by the Group's holding subsidiary Boan Biotech, has obtained the approval from the China’s National Medical Pro...
Luye Pharma Group today announced that the phase I clinical trial for LY-CovMab, an innovative antibody for the treatment of COVID-19, has been completed in China, with good results in safety and tole...
The COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a tremendous threat to human health and the global economy. LY-CovMab is a human monoclonal neutraliz...
Boan Biotech, a holding subsidiary of Luye Pharma Group, will present an abstract about the preclinical data on its CD3/CEA bispecific antibody program at the American Association for Cancer Research ...
Luye Pharma Group announced that the clinical trial application for LY01015 (Nivolumab Injection) developed by the Group's subsidiary Boan Biotech, has been accepted by the Center for Drug Evaluat...
Luye Pharma Group today announced that Shandong Boan Biotechnology Co. Ltd. (Boan Biotech) has completed the first patient dosing in the phase Ⅲ clinical trial for LY09004 in China. As a key area for...
Luye Pharma Group announced that its subsidiary, Shandong Boan Biotechnology Co. Ltd. (Boan Biotech), has received a further RMB 195 million in investments from investors including CCB International a...
Luye Pharma Group today announced that all subjects have been enrolled for the phase I clinical trial in China for LY-CovMab, an innovative antibody product developed by Shandong Boan Biotechnology Co...
Luye Pharma Group announced the conclusion of a round of strategic financing for its subsidiary, Shandong Boan Biotechnology Co., Ltd. (Boan Biotech), bringing cumulative financing to RMB 682 million....
Follow me
鲁公网安备37069102000284